Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin (Eurofarma) vs Zoladex in Premenopausal Breast Cancer
NCT03936933Phase 3Terminated
- Sponsor
- Eurofarma
- Start
- Oct 2020
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by Eurofarma. Primary endpoint: Pharmacodynamics at 85 days. Started Oct 2020; status: terminated.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03936933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936933.